1-20 of 42
leukemia, myelocytic, chronic
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Meeting the needs of CML patients in resource-poor countries

Hemant Malhotra, Jerald Radich, Pat Garcia-Gonzalez
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 433–442.
https://doi.org/10.1182/hematology.2019000050
Published: 2019
Journal Articles

Molecular monitoring in CML: how deep? How often? How should it influence therapy?

Naranie Shanmuganathan, Timothy P. Hughes
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 168–176.
https://doi.org/10.1182/asheducation-2018.1.168
Published: 2018
Journal Articles

The argument for using imatinib in CML

Simone Claudiani, Jane F. Apperley
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 161–167.
https://doi.org/10.1182/asheducation-2018.1.161
Published: 2018
Journal Articles

Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy

Mary C. Barber, Michael J. Mauro, Javid Moslehi
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 110–114.
https://doi.org/10.1182/asheducation-2017.1.110
Published: 2017
Journal Articles

Novel approaches to therapy in CML

Ravi Bhatia
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 115–120.
https://doi.org/10.1182/asheducation-2017.1.115
Published: 2017
Journal Articles

The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors

Fabio Efficace, Laura Cannella
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 170–179.
https://doi.org/10.1182/asheducation-2016.1.170
Published: 2016
Journal Articles

Molecular monitoring in chronic myeloid leukemia—how low can you go?

Susan Branford
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 156–163.
https://doi.org/10.1182/asheducation-2016.1.156
Published: 2016
Journal Articles

Chronic myeloid leukemia: sequencing of TKI therapies

Jorge Cortes, Hagop Kantarjian
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 164–169.
https://doi.org/10.1182/asheducation-2016.1.164
Published: 2016
Journal Articles

Molecular monitoring in CML and the prospects for treatment-free remissions

Michael W. Deininger
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 257–263.
https://doi.org/10.1182/asheducation-2015.1.257
Published: 2015
Journal Articles

Fertility issues in patients with hematologic malignancies

Alison W. Loren
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 138–145.
https://doi.org/10.1182/asheducation-2015.1.138
Published: 2015
Journal Articles

Maximizing GVL in allogeneic transplantation: role of donor lymphocyte infusions

Sarah Nikiforow, Edwin P. Alyea
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 570–575.
https://doi.org/10.1182/asheducation-2014.1.570
Published: 2014
Journal Articles

Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

David T. Yeung, Michael J. Mauro
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 240–243.
https://doi.org/10.1182/asheducation-2014.1.240
Published: 2014
Journal Articles

Goals for chronic myeloid leukemia TK inhibitor treatment: how little disease is too much?

Michael J. Mauro
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 234–239.
https://doi.org/10.1182/asheducation-2014.1.234
Published: 2014
Journal Articles

Update on current monitoring recommendations in chronic myeloid leukemia: practical points for clinical practice

Vivian G. Oehler
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 176–183.
https://doi.org/10.1182/asheducation-2013.1.176
Published: 2013
Journal Articles

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?

Kendra Sweet, Vivian Oehler
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 184–188.
https://doi.org/10.1182/asheducation-2013.1.184
Published: 2013
Journal Articles

Which TKI? An embarrassment of riches for chronic myeloid leukemia patients

Timothy Hughes, Deborah White
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 168–175.
https://doi.org/10.1182/asheducation-2013.1.168
Published: 2013
Journal Articles

Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond

Wesam Ahmed, Richard A. Van Etten
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 189–200.
https://doi.org/10.1182/asheducation-2013.1.189
Published: 2013
Journal Articles

Monitoring after successful therapy for chronic myeloid leukemia

Susan Branford
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 105–110.
https://doi.org/10.1182/asheducation.V2012.1.105.3798223
Published: 2012
Journal Articles

Monitoring disease response in chronic-phase chronic myeloid leukemia: the age of molecular assays?

David T. Yeung, Susan Branford
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 111–114.
https://doi.org/10.1182/asheducation.V2012.1.111.3806846
Published: 2012
Journal Articles

Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia

David Marin
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 115–121.
https://doi.org/10.1182/asheducation.V2012.1.115.3798209
Published: 2012